Perioperative chemotherapy for resectable gastric cancer – what is the evidence?

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386.
   PubMed Web of Science ®Google Scholar
• Nitti D, Wils J, Dos Santos JG, et al. Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. Ann Oncol. 2006;17:262–269.
   PubMed Web of Science ®Google Scholar
• Bajetta E, Floriani I, Di Bartolomeo M, on behalf of ITACA-S Study Group, et al. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. Ann Oncol. 2014;25:1373–1378.
   PubMed Web of Science ®Google Scholar
• Hermans J, Bonenkamp JJ, Boon MC, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol. 1993;11:1441–1447.
   PubMed Web of Science ®Google Scholar
• Janunger KG, Hafstrøm L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg. 2002;168:597–508.
   PubMedGoogle Scholar
• Paoletti X, Oba K, Burzykowski T, on behalf of the Global Advanced/Adjuvant Stomach Tumour Research International Collaboration Group, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer. Metaanalysis JAMA. 2010;303:1729–1737.
   PubMed Web of Science ®Google Scholar
• Chua YJ, Cunningham D. The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice. Ann Surg Oncol. 2007;14:2687–2690.
   PubMed Web of Science ®Google Scholar
• Davies AR, Gossage JA, Zylstra J, et al. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction. J Clin Oncol. 2014;32:2983–2990.
   PubMed Web of Science ®Google Scholar
• Mansour JC, Schwarz ER. Pathologic response to preoperative therapy: does it mean what we think it means? Ann Surg Oncol. 2009;16:1465–1479.
   PubMed Web of Science ®Google Scholar
• Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954. J Clin Oncol. 2010;28:5210–5218.
   PubMed Web of Science ®Google Scholar
• Klevebro F, von Döbeln GA, Wang N, et al. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol. 2016; 27:660–667.
   PubMed Web of Science ®Google Scholar
• Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–730.
   PubMed Web of Science ®Google Scholar
• Hundahl SA, Macdonald JS, Benedetti J, Southwest Oncology Group and the Gastric Intergroup, et al. Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. Ann Surg Oncol. 2002;9:278–286.
   PubMed Web of Science ®Google Scholar
• Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30:2327–2333.
   PubMed Web of Science ®Google Scholar
• Cuschieri SA, Hanna GB. Meta-analysis of D1 versus D2 gastrectomy for gastric adenocarcinoma: let us move on to another era. Ann Surg. 2014;259:e90.
   Google Scholar
• Dikken JL, Jansen EP, Cats A, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol. 2010;28:2430–2436.
   PubMed Web of Science ®Google Scholar
• Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–4393.
   PubMed Web of Science ®Google Scholar
• Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomized controlled trial. Lancet. 2012;379:315–321.
   PubMed Web of Science ®Google Scholar
• Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–221.
   PubMed Web of Science ®Google Scholar
• Lee J, Lim DH, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30:268–273.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.
   PubMed Web of Science ®Google Scholar
• Okines A, Verheij M, Allum WH, et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:50–54.
   PubMed Web of Science ®Google Scholar
• Allum WH, Blazeby JM, Griffin SM, Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, British Society of Gastroenterology and British Association of Surgical Oncology, et al. Guidelines for the management of oesophageal and gastric cancer. Gut. 2011;60:1449–1472.
   PubMed Web of Science ®Google Scholar
• Bauer K, Porzsolt F, Henne-Brun D. Can perioperative chemotherapy for advanced gastric cancer be recommended on the basis of current research? A critical analysis. J Gastric Cancer. 2014;14:39–46.
   PubMedGoogle Scholar
• Hartgrink HH, van de Velde CJH, Putter H, et al. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol. 2004;30:643–649.
   PubMed Web of Science ®Google Scholar
• Bonenkamp JJ, Hermans J, Sasako M, Dutch Gastric Cancer Group, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340:908–914.
   PubMed Web of Science ®Google Scholar
• Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer. 1999;79:1522–1530.
   PubMed Web of Science ®Google Scholar
• Moorcraft SY, Smyth EC, Cunningham D. Adjuvant or neoadjuvant therapy for operable esophagogastric cancer? Gastric Cancer. 2015;18:1–10.
   PubMed Web of Science ®Google Scholar
• Rutgård M, Shore R, Lu Y, et al. Sex differences in the incidence of gastrointestinal adenocarcinoma in Sweden 1970-2006. Eur J Cancer. 2010;46:1093–1000.
   PubMed Web of Science ®Google Scholar
• Bringeland EA, Wasmuth HH, Mjønes P, et al. A population-based study on incidence rates, Lauren distribution, stage distribution, treatment, and long-term outcomes for gastric adenocarcinoma in Central Norway 2001-2011. Acta Oncol. 2017;56:39–45.
   PubMed Web of Science ®Google Scholar
• Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.
   PubMedGoogle Scholar
• Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data. Eur J Cancer. 2013;49:3149–3158.
   PubMed Web of Science ®Google Scholar
• Bringeland EA, Wasmuth HH, Fougner R, et al. Impact of perioperative chemotherapy on oncological outcomes after gastric cancer surgery. Br J Surg. 2014;101:1712–1720.
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicenter, open-label, randomized phase 2/3 trial. The Lancet Oncol. 2016;17:1697–1708.
   PubMed Web of Science ®Google Scholar
• Heger U, Blank S, Wiecha C, et al. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach? Ann Surg Oncol. 2014;21:1739–1748.
   PubMed Web of Science ®Google Scholar
• Larsen AC, Holländer C, Duval L, et al. A nationwide retrospective study of perioperative chemotherapy for gastroesophageal adenocarcinoma: tolerability, outcome and prognostic factors. Ann Surg Oncol. 2015;22:1540–1547.
   PubMed Web of Science ®Google Scholar
• Leong T, Smithers BM, Michael M, et al. TOPGEAR: a randomized phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer. BMC Cancer. 2015;15:532–538.
   PubMed Web of Science ®Google Scholar
• Kumagai K, Rouvelas I, Tsai JA, et al. Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: a direct and adjusted indirect comparison meta-analysis. Eur J Surg Oncol. 2015;41:282–294.
   PubMed Web of Science ®Google Scholar
• Ychou M, Boige V, Pignon J-P, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715–1721.
   PubMed Web of Science ®Google Scholar
• Strobel O, Büchler MW. The problem of the poor control arm in surgical randomized controlled trials. Br J Surg. 2013;100:172–173.
   PubMed Web of Science ®Google Scholar
• Reece-Smith AM, Saha S, Cunnell ML, et al. MAGIC in practice: experience of peri-operative ECF/X chemotherapy in gastro-esophageal adenocarcinomas. J Surg Oncol. 2012;106:748–752.
   PubMed Web of Science ®Google Scholar
• Molina R, Lamarca A, Martinez-Amores B, et al. Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience. Eur J Surg Oncol. 2013;39:814–822.
   PubMed Web of Science ®Google Scholar
• Mingol F, Gallego J, Orduna A, et al. Tumor regression and survival after periopereative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction. BMC Surg. 2015;15:66–75.
   PubMed Web of Science ®Google Scholar
• Hølmebakk T, Frykholm G, Viste A. Norwegian Gastrointestinal Cancer Group (NGICG). Introducing national guidelines on perioperative chemotherapy for gastric cancer in Norway: a retrospective audit. Eur J Surg Oncol. 2010;36:610–616.
   PubMed Web of Science ®Google Scholar
• Dikken JL, van Sandick JW, Swellengrebel HAM, et al. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiothearapy for patients with resectable gastric cancer (CRITICS). BMC Cancer. 2011;11:329–337.
   PubMed Web of Science ®Google Scholar
• Verheij M, Jansen EPM, Cats A, et al. A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: first results from the CRITICS study. J Clin Oncol. 2016; 34 Available at http://meetinglibrary.asco.org/content/165706-176
   Google Scholar
• Okines AF, Langley RE, Thompson LC, et al. Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report. Ann Oncol. 2013;24:702–709.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Smyth E, Stenning S, Stevenson L, Robb C, Allum W, et al. Peri-operative chemotherapy ± bevacizumab for resectable gastro-oesophageal adenocarcinoma: results from the UK medical Research Council randomized ST03 trial (ISRCTN 46020948). Eur J Cancer. 2015;51:S400.
   Web of Science ®Google Scholar
• Li W, Qin J, Sun YH, et al. Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. World J Gastroenterol. 2010;16:5621–5628.
   PubMed Web of Science ®Google Scholar
• Xu AM, Huang L, Liu W, et al. Neoadjuvant chemotherapy followed by surgery versus surgery alone for gastric carcinoma: systematic review and meta-analysis of randomized controlled trials. PLoS One. 2014;9:e86941.
   PubMed Web of Science ®Google Scholar
• Ge L, Wang HJ, Yin D, et al. Effectiveness of 5-flurouracil-based neoadjuvant chemotherapy in locally-advanced gastric/gastroesophageal cancer: a meta-analysis. WJG. 2012;18:7384–7393.
   PubMed Web of Science ®Google Scholar
• Liao Y, Yang ZL, Peng JS, et al. Neoadjuvant chemotherapy for gastric cancer: a meta-analysis of randomized, controlled trials. J Gastroenterol Hepatol. 2013;28:777–782.
   PubMed Web of Science ®Google Scholar
• Zhang CD, Zeng YJ, Li HW, et al. Neoadjuvant chemotherapy for nonmetastatic esophago-gastric adenocarcinomas: a systematic review and meta-analysis. Cancer Invest. 2013;31:421–431.
   PubMed Web of Science ®Google Scholar
• Reim D, Gertler R, Novotny A, et al. Adenocarcinoma of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer. Ann Surg Oncol. 2012;19:2108–2118.
   PubMed Web of Science ®Google Scholar
• Bass AJ. On behalf of Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–209.
   PubMed Web of Science ®Google Scholar
• Choi YY, Noh SH, Cheong JH. Molecular dimensions of gastric cancer: translational and clinical perspectives. J Pathol Transl Med. 2016;50:1–9.
   PubMedGoogle Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial . Lancet. 2010;376:687–697.
   PubMed Web of Science ®Google Scholar
• Hecht JR, Bang YJ, Qin SK, et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC-A randomized phase III trial. J Clin Oncol. 2016;34:443–451.
   PubMed Web of Science ®Google Scholar